The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Isocitrate Dehydrogenase Inhibitors Market Research Report 2025
Synopsis
Isocitrate dehydrogenase (IDH) (EC 1.1.1.42) and (EC 1.1.1.41) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2.
The global Isocitrate Dehydrogenase Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Specific mutations in the isocitrate dehydrogenase gene IDH1 have been found in several brain tumors including astrocytoma, oligodendroglioma and glioblastoma multiforme, with mutations found in nearly all cases of secondary glioblastomas, which develop from lower-grade gliomas, but rarely in primary high-grade glioblastoma multiforme.Patients whose tumor had an IDH1 mutation had longer survival. Furthermore, mutations of IDH2 and IDH1 were found in up to 20% of cytogenetically normal acute myeloid leukemia (AML).These mutations are known to produce (D)-2-hydroxyglutarate from alpha-ketoglutarate.(D)-2-hydroxyglutarate accumulates to very high concentrations which inhibits the function of enzymes that are dependent on alpha-ketoglutarate.This leads to a hypermethylated state of DNA and histones, which results in different gene expression that can activate oncogenes and inactivate tumor-suppressor genes. Ultimately, this may lead to the types of cancer described above.Isocitrate dehydrogenase inhibition technology can be effectively applied to the cancer market.
This report aims to provide a comprehensive presentation of the global market for Isocitrate Dehydrogenase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Isocitrate Dehydrogenase Inhibitors.
Report Scope
The Isocitrate Dehydrogenase Inhibitors market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Isocitrate Dehydrogenase Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Isocitrate Dehydrogenase Inhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AGIOS
Aslan Pharmaceuticals
Bayer
Beigene
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Philogen S.p.A.
Tesaro
Tragara/Adastra
Tocagen
Segment by Type
IDH1 Mutant Medullary Malignant Tumor
IDH2 Mutant Medullary Malignant Tumor
Others
Segment by Application
DH Inhibitor
FLT3 Inhibitor
Hedgehog Pathway Inhibitor
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Isocitrate Dehydrogenase Inhibitors companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Isocitrate dehydrogenase (IDH) (EC 1.1.1.42) and (EC 1.1.1.41) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2.
The global Isocitrate Dehydrogenase Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Specific mutations in the isocitrate dehydrogenase gene IDH1 have been found in several brain tumors including astrocytoma, oligodendroglioma and glioblastoma multiforme, with mutations found in nearly all cases of secondary glioblastomas, which develop from lower-grade gliomas, but rarely in primary high-grade glioblastoma multiforme.Patients whose tumor had an IDH1 mutation had longer survival. Furthermore, mutations of IDH2 and IDH1 were found in up to 20% of cytogenetically normal acute myeloid leukemia (AML).These mutations are known to produce (D)-2-hydroxyglutarate from alpha-ketoglutarate.(D)-2-hydroxyglutarate accumulates to very high concentrations which inhibits the function of enzymes that are dependent on alpha-ketoglutarate.This leads to a hypermethylated state of DNA and histones, which results in different gene expression that can activate oncogenes and inactivate tumor-suppressor genes. Ultimately, this may lead to the types of cancer described above.Isocitrate dehydrogenase inhibition technology can be effectively applied to the cancer market.
This report aims to provide a comprehensive presentation of the global market for Isocitrate Dehydrogenase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Isocitrate Dehydrogenase Inhibitors.
Report Scope
The Isocitrate Dehydrogenase Inhibitors market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Isocitrate Dehydrogenase Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Isocitrate Dehydrogenase Inhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AGIOS
Aslan Pharmaceuticals
Bayer
Beigene
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Philogen S.p.A.
Tesaro
Tragara/Adastra
Tocagen
Segment by Type
IDH1 Mutant Medullary Malignant Tumor
IDH2 Mutant Medullary Malignant Tumor
Others
Segment by Application
DH Inhibitor
FLT3 Inhibitor
Hedgehog Pathway Inhibitor
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Isocitrate Dehydrogenase Inhibitors companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Isocitrate Dehydrogenase Inhibitors Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 IDH1 Mutant Medullary Malignant Tumor
1.2.3 IDH2 Mutant Medullary Malignant Tumor
1.2.4 Others
1.3 Market by Application
1.3.1 Global Isocitrate Dehydrogenase Inhibitors Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 DH Inhibitor
1.3.3 FLT3 Inhibitor
1.3.4 Hedgehog Pathway Inhibitor
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Isocitrate Dehydrogenase Inhibitors Market Perspective (2019-2030)
2.2 Isocitrate Dehydrogenase Inhibitors Growth Trends by Region
2.2.1 Global Isocitrate Dehydrogenase Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Isocitrate Dehydrogenase Inhibitors Historic Market Size by Region (2019-2024)
2.2.3 Isocitrate Dehydrogenase Inhibitors Forecasted Market Size by Region (2025-2030)
2.3 Isocitrate Dehydrogenase Inhibitors Market Dynamics
2.3.1 Isocitrate Dehydrogenase Inhibitors Industry Trends
2.3.2 Isocitrate Dehydrogenase Inhibitors Market Drivers
2.3.3 Isocitrate Dehydrogenase Inhibitors Market Challenges
2.3.4 Isocitrate Dehydrogenase Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Isocitrate Dehydrogenase Inhibitors Players by Revenue
3.1.1 Global Top Isocitrate Dehydrogenase Inhibitors Players by Revenue (2019-2024)
3.1.2 Global Isocitrate Dehydrogenase Inhibitors Revenue Market Share by Players (2019-2024)
3.2 Global Isocitrate Dehydrogenase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Isocitrate Dehydrogenase Inhibitors Revenue
3.4 Global Isocitrate Dehydrogenase Inhibitors Market Concentration Ratio
3.4.1 Global Isocitrate Dehydrogenase Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Isocitrate Dehydrogenase Inhibitors Revenue in 2023
3.5 Isocitrate Dehydrogenase Inhibitors Key Players Head office and Area Served
3.6 Key Players Isocitrate Dehydrogenase Inhibitors Product Solution and Service
3.7 Date of Enter into Isocitrate Dehydrogenase Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Isocitrate Dehydrogenase Inhibitors Breakdown Data by Type
4.1 Global Isocitrate Dehydrogenase Inhibitors Historic Market Size by Type (2019-2024)
4.2 Global Isocitrate Dehydrogenase Inhibitors Forecasted Market Size by Type (2025-2030)
5 Isocitrate Dehydrogenase Inhibitors Breakdown Data by Application
5.1 Global Isocitrate Dehydrogenase Inhibitors Historic Market Size by Application (2019-2024)
5.2 Global Isocitrate Dehydrogenase Inhibitors Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Isocitrate Dehydrogenase Inhibitors Market Size (2019-2030)
6.2 North America Isocitrate Dehydrogenase Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Isocitrate Dehydrogenase Inhibitors Market Size by Country (2019-2024)
6.4 North America Isocitrate Dehydrogenase Inhibitors Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Isocitrate Dehydrogenase Inhibitors Market Size (2019-2030)
7.2 Europe Isocitrate Dehydrogenase Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Isocitrate Dehydrogenase Inhibitors Market Size by Country (2019-2024)
7.4 Europe Isocitrate Dehydrogenase Inhibitors Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Size (2019-2030)
8.2 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Size by Region (2019-2024)
8.4 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Isocitrate Dehydrogenase Inhibitors Market Size (2019-2030)
9.2 Latin America Isocitrate Dehydrogenase Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Isocitrate Dehydrogenase Inhibitors Market Size by Country (2019-2024)
9.4 Latin America Isocitrate Dehydrogenase Inhibitors Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Size (2019-2030)
10.2 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Size by Country (2019-2024)
10.4 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AGIOS
11.1.1 AGIOS Company Detail
11.1.2 AGIOS Business Overview
11.1.3 AGIOS Isocitrate Dehydrogenase Inhibitors Introduction
11.1.4 AGIOS Revenue in Isocitrate Dehydrogenase Inhibitors Business (2019-2024)
11.1.5 AGIOS Recent Development
11.2 Aslan Pharmaceuticals
11.2.1 Aslan Pharmaceuticals Company Detail
11.2.2 Aslan Pharmaceuticals Business Overview
11.2.3 Aslan Pharmaceuticals Isocitrate Dehydrogenase Inhibitors Introduction
11.2.4 Aslan Pharmaceuticals Revenue in Isocitrate Dehydrogenase Inhibitors Business (2019-2024)
11.2.5 Aslan Pharmaceuticals Recent Development
11.3 Bayer
11.3.1 Bayer Company Detail
11.3.2 Bayer Business Overview
11.3.3 Bayer Isocitrate Dehydrogenase Inhibitors Introduction
11.3.4 Bayer Revenue in Isocitrate Dehydrogenase Inhibitors Business (2019-2024)
11.3.5 Bayer Recent Development
11.4 Beigene
11.4.1 Beigene Company Detail
11.4.2 Beigene Business Overview
11.4.3 Beigene Isocitrate Dehydrogenase Inhibitors Introduction
11.4.4 Beigene Revenue in Isocitrate Dehydrogenase Inhibitors Business (2019-2024)
11.4.5 Beigene Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Detail
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Isocitrate Dehydrogenase Inhibitors Introduction
11.5.4 Bristol-Myers Squibb Revenue in Isocitrate Dehydrogenase Inhibitors Business (2019-2024)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Celgene
11.6.1 Celgene Company Detail
11.6.2 Celgene Business Overview
11.6.3 Celgene Isocitrate Dehydrogenase Inhibitors Introduction
11.6.4 Celgene Revenue in Isocitrate Dehydrogenase Inhibitors Business (2019-2024)
11.6.5 Celgene Recent Development
11.7 Daiichi Sankyo
11.7.1 Daiichi Sankyo Company Detail
11.7.2 Daiichi Sankyo Business Overview
11.7.3 Daiichi Sankyo Isocitrate Dehydrogenase Inhibitors Introduction
11.7.4 Daiichi Sankyo Revenue in Isocitrate Dehydrogenase Inhibitors Business (2019-2024)
11.7.5 Daiichi Sankyo Recent Development
11.8 Philogen S.p.A.
11.8.1 Philogen S.p.A. Company Detail
11.8.2 Philogen S.p.A. Business Overview
11.8.3 Philogen S.p.A. Isocitrate Dehydrogenase Inhibitors Introduction
11.8.4 Philogen S.p.A. Revenue in Isocitrate Dehydrogenase Inhibitors Business (2019-2024)
11.8.5 Philogen S.p.A. Recent Development
11.9 Tesaro
11.9.1 Tesaro Company Detail
11.9.2 Tesaro Business Overview
11.9.3 Tesaro Isocitrate Dehydrogenase Inhibitors Introduction
11.9.4 Tesaro Revenue in Isocitrate Dehydrogenase Inhibitors Business (2019-2024)
11.9.5 Tesaro Recent Development
11.10 Tragara/Adastra
11.10.1 Tragara/Adastra Company Detail
11.10.2 Tragara/Adastra Business Overview
11.10.3 Tragara/Adastra Isocitrate Dehydrogenase Inhibitors Introduction
11.10.4 Tragara/Adastra Revenue in Isocitrate Dehydrogenase Inhibitors Business (2019-2024)
11.10.5 Tragara/Adastra Recent Development
11.11 Tocagen
11.11.1 Tocagen Company Detail
11.11.2 Tocagen Business Overview
11.11.3 Tocagen Isocitrate Dehydrogenase Inhibitors Introduction
11.11.4 Tocagen Revenue in Isocitrate Dehydrogenase Inhibitors Business (2019-2024)
11.11.5 Tocagen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
